Prevalence and healthcare burden of pulmonary alveolar proteinosis

Table 1 Study Population and Annual Prevalence of PAP Syndrome in the US^a

Study year	Total patients^b	Total PAP patients^c	Total PAP prevalence per million patients^d
2008	15,519,985	105	6.77
2009	15,686,604	127	8.10
2010	16,070,700	103	6.41
2011	15,764,422	109	6.91
2012	16,515,902	102	6.18
Mean	15,911,523	109	6.87
Study year	Total female patients^b	Female PAP patients^c	PAP prevalence per million female patients^e
2008	7,953,672	51	6.41
2009	8,038,763	67	8.33
2010	8,233,635	57	6.92
2011	8,069,748	67	8.30
2012	8,427,886	59	7.00
Mean	8,144,741	60	7.39
Study year	Total male patients^b	Male PAP patients^c	PAP prevalence per million male patients^f
2008	7,566,313	54	7.14
2009	7,647,841	60	7.85
2010	7,837,065	46	5.87
2011	7,694,674	42	5.46
2012	8,088,016	43	5.32
Mean	7,766,782	49	6.31

Definition of abbreviations: PAP pulmonary alveolar proteinosis
^aPatients are individuals represented by de-identified data in the OptumInsight database during the study period meeting the inclusion and exclusion criteria as defined in the methods
^bIncludes all (or female/male patients as indicated) with complete annual claims data for at least two consecutive years
^cIncludes all (or female/male patients as indicated) patients with at least one claim associated with an ICD-9516.0 code in the respective calendar year
^dCalculated as the number of PAP patients in each year divided by the total number of patients included in that year
^eCalculated as the number of female PAP patients in each year divided by the number of female patients included in that year
^fCalculated as the number of male PAP patients in each year divided by the number of male patients included in that year

ISSN: 1750-1172